Provided by Tiger Fintech (Singapore) Pte. Ltd.

LUCID DIAGNOSTICS INC.

1.39
+0.11008.59%
Post-market: 1.420.0287+2.06%19:59 EDT
Volume:1.22M
Turnover:1.70M
Market Cap:101.86M
PE:-1.24
High:1.46
Open:1.31
Low:1.29
Close:1.28
Loading ...

Company Profile

Company Name:
LUCID DIAGNOSTICS INC.
Exchange:
NASDAQ
Establishment Date:
2018
Employees:
70
Office Location:
360 Madison Avenue,25th Floor,New York,New York,United States
Zip Code:
10017
Fax:
- -
Introduction:
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.

Directors

Name
Position
Lishan Aklog
Chairman and Chief Executive Officer
Stanley N. Lapidus
Vice Chairman and Director
Debra J. White
Director
Jacque J. Sokolov
Director
James L. Cox
Director
Ronald M. Sparks
Director

Shareholders

Name
Position
Lishan Aklog
Chairman and Chief Executive Officer
Shaun M. O'Neil
Chief Operating Officer
Dennis M. McGrath
Chief Financial Officer
Michael A. Gordon
General Counsel and Secretary